Shopping Cart
- Remove All
- Your shopping cart is currently empty
BF-168 is a candidate probe for PET and specifically recognizes both neuritic and diffuse plaques (Ki: 6.4 nM for Aβ1-42).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $376 | 10-14 weeks | |
25 mg | $1,140 | 10-14 weeks | |
50 mg | $1,490 | 10-14 weeks | |
100 mg | $2,360 | 10-14 weeks |
Description | BF-168 is a candidate probe for PET and specifically recognizes both neuritic and diffuse plaques (Ki: 6.4 nM for Aβ1-42). |
Targets&IC50 | β-Amyloid (1–42):ki: 6.4 nM |
In vitro | BF-168 is a potent agent that selectively recognizes SPs and NFTs in AD brain. BF-168 is a candidate probe for PET and is found to specifically recognize both neuritic and diffuse plaques. |
In vivo | Intravenous injection of BF-168 in PS1/APP and APP23 transgenic mice results in specific in vivo labeling of both compact and diffuse amyloid deposits in the brain. Additionally, 18F-radiolabeled BF-168 demonstrates significant initial brain uptake (3.9% injected dose/gm at 2 min post-injection) and rapid clearance (t1/2=24.7 min) after intravenous administration in normal mice. |
Molecular Weight | 312.34 |
Formula | C18H17FN2O2 |
Cas No. | 634911-47-0 |
Relative Density. | 1.258 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.